Zenotech Laboratories Share Price
44.16-0.08 (-1.87%)
-15.95% past 1 Year
Corporate filings & documents
Announcements
Newspaper publication informing about 37th Annual General Meeting & e-Voting.
3 weeks agoNewspaper publication informing about 37th Annual General Meeting & e-Voting.
3 weeks agoNotice of 37th Annual General Meeting along with Annual Report for the FY 2025-26
3 weeks agoNotice of 37th Annual General Meeting along with Annual Report for the FY 2025-26
3 weeks agoAnnual Report 2025-26 and the Notice of 37th Annual General Meeting
3 weeks agoAnnual Report 2025-26 and the Notice of 37th Annual General Meeting
3 weeks agoNewspaper Advertisement
3 weeks agoNewspaper Advertisement
3 weeks agoIntimation of 37th Annual General Meeting of the Company to be held on Friday September 25 2026 at 10:30 a.m. IST through Video Conferencing mode.
4 weeks agoIntimation of 37th Annual General Meeting of the Company to be held on Friday September 25 2026 at 10:30 a.m. IST through Video Conferencing mode.
4 weeks agoPublication of extract of Unaudited Financial Results for the quarter ended June 30 2026 in newspapers.
1 month agoPublication of extract of Unaudited Financial Results for the quarter ended June 30 2026 in newspapers.
1 month agoOutcome of the Board Meeting held today i.e. July 28 2026
1 month agoOutcome of the Board Meeting held today i.e. July 28 2026
1 month agoSubmission of Unaudited Financial Results of the Company for the quarter ended June 30 2026.
1 month agoSubmission of Unaudited Financial Results of the Company for the quarter ended June 30 2026.
1 month agoSubmission of Compliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended June 30 2026.
2 months agoSubmission of Compliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended June 30 2026.
2 months agoZenotech Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 inter alia to consider and approve Unaudited Standalone Financial Results for the quarter ended June 30 2026.
2 months agoZenotech Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 inter alia to consider and approve Unaudited Standalone Financial Results for the quarter ended June 30 2026.
2 months agoClosure of Trading Window
2 months agoClosure of Trading Window
2 months agoSubmission of Annual Secretarial Compliance Report for the financial year 2025-26
3 months agoCopies of extract of Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31 2026 as published in todays newspaper i.e. April 30 2026.
4 months agoCopies of extract of Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31 2026 as published in todays newspaper i.e. April 30 2026.
4 months agoAudited Standalone Financial Results for the quarter and financial year ended March 31 2026 and declaration of unmodified opinion on the Financial Results.
4 months agoSubmission of Audited Standalone Financial Results for the quarter and financial year ended March 31 2026
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Zenotech Laboratories Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L27100TG1989PLC010122</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>Nil</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Abdul Gafoor Mohammad <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Poly KV <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 28/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoZenotech Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2026 inter alia to consider and approve Audited Standalone Financial Results for the quarter and financial year ended March 31 2026.
5 months agoZenotech Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2026 inter alia to consider and approve Audited Standalone Financial Results for the quarter and financial year ended March 31 2026.
5 months agoClarification on Price Movement is enclosed herewith
5 months agoClarification on Price Movement is enclosed herewith
5 months agoThe Exchange has sought clarification from Zenotech Laboratories Ltd on April 9 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
5 months agoThe Exchange has sought clarification from Zenotech Laboratories Ltd on April 9 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
5 months agoSubmission of Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended March 31 2026.
5 months agoSubmission of Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended March 31 2026.
5 months agoIntimation for Trading Window Closure
5 months agoSubmission of Scrutinizers Report dated March 12 2026 for Postal Ballot event.
6 months agoSubmission of Scrutinizers Report dated March 12 2026 for Postal Ballot event.
6 months agoResult of the Postal Ballot by Remote e-Voting process and submission of Scrutinizers Report dated March 12 2026.
6 months agoResult of the Postal Ballot by Remote e-Voting process and submission of Scrutinizers Report dated March 12 2026.
6 months agoCopies of Newspaper Advertisement published today i.e. February 10 2026 regarding Notice of Postal Ballot & e-voting with Digital Signature affixed.
7 months agoCopies of Newspaper Advertisement published today i.e. February 10 2026 regarding Notice of Postal Ballot & e-voting.
7 months agoNotice of Postal Ballot dated January 23 2026 is attached.
7 months agoCopies of extracts of Standalone Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2025 published in newspapers today i.e. January 24 2026.
7 months agoOutcome of the Board Meeting held today i.e. January 23 2026
8 months agoUnaudited Financial Results for the quarter and nine months ended December 31 2025
8 months agoZenotech Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2026 inter alia to consider and approve Unaudited Standalone Financial Results for the quarter and nine months ended December 31 2025.
8 months agoCompliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 is attached.
8 months agoIntimation of closure of Trading Window for the quarter and nine months ending December 31 2025.
8 months agoAnnual reports
Concalls & investor presentations
No presentations found